NovoCure Limited Ordinary Shares (NVCR)

NVCR receives FDA approval for pancreatic cancer treatment, boosting survival rates. Despite positive news, the stock faces downward pressure due to broader market trends.

About NovoCure Limited Ordinary Shares

NovoCure Limited Ordinary Shares (NVCR) is a healthcare company focused on TTFields therapy for cancer treatment.
NovoCure Limited Ordinary Shares uses the ticker $NVCR for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

NovoCure Limited Ordinary Shares (NVCR) trading volume is up 182.63% from the previous week.
NovoCure Limited Ordinary Shares (NVCR) market cap is up 10.68% from the previous week.
NovoCure Limited Ordinary Shares (NVCR) social dominance is up 1088.89% from the previous [--] months.
NovoCure Limited Ordinary Shares (NVCR) creators is up 1839.29% from the previous week.
NovoCure Limited Ordinary Shares (NVCR) engagements is up 863.78% from the previous week.
NovoCure Limited Ordinary Shares (NVCR) mentions is up 1518% from the previous week.
NovoCure Limited Ordinary Shares (NVCR) posts created is up 7083.33% from the previous week.
NovoCure Limited Ordinary Shares Creators hit a 52-Week high of [---] for the day
NovoCure Limited Ordinary Shares Creators hit an all time of [---] for the day
NovoCure Limited Ordinary Shares Engagements hit a 52-Week high of [-------] for the day
NovoCure Limited Ordinary Shares Mentions hit a 52-Week high of [---] for the day

Price: $11

Price 24-Hour Time-Series Raw Data
Despite positive news like FDA approval for pancreatic cancer treatment, NVCR's price is experiencing downward pressure, likely due to broader market trends that are currently outweighing the positive social and corporate developments.

24-Hour: -12.36% 7-Day: 7.75% 30-Day: -19.43%

1-Year High: $22.50 on 2025-02-17
1-Year Low: $10 on 2026-02-09

AltRank: [---]

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
NovoCure Limited Ordinary Shares (NVCR) is currently AltRank #710 based on combined combined social and market metrics Daily Average: [-----]
[--] Week: [---] [------]
[--] Month: [---] +360
[--] Months: [---] [----]
[--] Year: [---] [----]
1-Year High: [-----] on 2026-01-29
1-Year Low: [--] on 2025-11-01

Galaxy Score: [-----]

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-06-10
1-Year Low: [--] on 2025-10-30

Engagements: [------] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [-----]
[--] Week: [-------] +864%
[--] Month: [-------] +497%
[--] Months: [-------] +14%
[--] Year: [---------] -59%
1-Year High: [-------] on 2026-02-12
1-Year Low: [--] on 2025-12-21

Engagements by network (24h): TikTok: [--] News: [--] X: [------] Reddit: [--] YouTube: [--]

Mentions: [---] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
[--] Week: [---] +1,518%
[--] Month: [---] +429%
[--] Months: [-----] +2.60%
[--] Year: [-----] -4.50%
1-Year High: [---] on 2026-02-12
1-Year Low: [--] on 2025-12-21

Mentions by network (24h): TikTok: [--] News: [--] X: [---] Reddit: [--] YouTube: [--]

Creators: [---] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning NovoCure Limited Ordinary Shares (NVCR) in the last [--] hours which is down 46% from [---] in the previous [--] hours Daily Average: [--]
[--] Week: [---] +1,839%
[--] Month: [---] +475%
[--] Months: [---] -18%
[--] Year: [-----] +35%
1-Year High: [---] on 2026-02-12
1-Year Low: [--] on 2025-12-21

The most influential creators that mention NovoCure Limited Ordinary Shares in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	[--]	[------]	[--]	[-----]
@ATP_Analytics	[--]	[-----]	[--]	[---]
@LayanAhmed5637	[--]	[--]	[--]	[---]
@goldchart2	[--]	[---]	[--]	[---]
@Pro_Trader0000	[--]	[--]	[--]	[--]
@MiriamF24887120	[--]	[--]	[--]	[--]
@NightOwlBiotech	[--]	[-----]	[--]	[--]
@RosaJim94865433	[--]	[---]	[--]	[--]
@TohJah7809	[--]	[-----]	[--]	[--]
@Angelinafrazier	[--]		[--]	[--]

Sentiment: 75%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 75%
Daily Average: 71%
[--] Week: 80% -20%
[--] Month: 74% +41%
[--] Months: 74% +12%
[--] Year: 74% -12%
1-Year High: 100% on 2025-02-26
1-Year Low: 8% on 2026-01-11

Most Supportive Themes:

FDA Approval for Pancreatic Cancer Treatment: (50%) NovoCure's Optune Pax device has received FDA approval for treating locally advanced pancreatic cancer, marking a significant advancement in treatment options.
Positive Clinical Trial Data: (30%) The PANOVA-3 trial demonstrated improved overall survival and extended time to pain progression for patients using Optune Pax, highlighting the therapy's efficacy.

Most Critical Themes:

Market Trends Impacting Price: (70%) Broader market trends are currently exerting downward pressure on NVCR's stock price, overshadowing positive company news and developments.

Social Dominance: 0.017%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.017%
Daily Average: 0.00644%
[--] Week: 0.021% +0.018%
[--] Month: 0.032% +0.029%
[--] Months: 0.032% +0.025%
[--] Year: 0.032% +0.025%
1-Year High: 0.048% on 2026-02-12
1-Year Low: 0.0003% on 2025-12-21

Market Dominance: 0.0014%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.0014%
Daily Average: 0%
1-Year High: 0.00879% on 2025-03-31
1-Year Low: 0.00129% on 2026-02-09

Market Cap: $1,232,921,611

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $1,232,921,611
Daily Average: $1,658,785,774
[--] Week: $1,233,190,368 +11%
[--] Month: $1,230,681,971 -19%
[--] Months: $1,230,681,971 -6.60%
[--] Year: $1,230,681,971 -49%
1-Year High: $2,432,368,236 on 2025-02-17
1-Year Low: $1,123,179,269 on 2026-02-09

Top NovoCure Limited Ordinary Shares Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"Today's Active HTB Locates: 29.9% $CRSR 26.1% $FSLY 9.1% $MLEC 7.5% $INTC 5.4% $SNDK 3.8% $JDZG 3.8% $IMUX 3.7% $MSTR 3.7% $NVCR 3.7% $UPST 1.9% $WULF 1.2% $ASTS 0.0% $RIME AlphaTraderPro Analytics: https://t.me/alphatraderpro_analytics https://t.me/alphatraderpro_analytics"
X Link @ATP_Analytics 2026-02-16T13:00Z [----] followers, [---] engagements

"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $BIVI Phase [--] $MDNAF Phase 2b $DBVT Phase [--] $GOSS Phase [--] $MLTX Phase [--] $BFRI Phase [--] $BCDA Phase [--] $KPTI Phase [--] $IOVA Phase [--] $XENE Phase [--] $AGIO Phase 2b $AVBP Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $IDYA Phase 2/3 $VXRT Phase 2b $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $ALZN Phase [--] $HELP Phase [--] $PVLA Phase [--] $INSM"
X Link @BiopharmIQ 2026-02-15T19:38Z 28.9K followers, [----] engagements

"🧬 Weekly & YTD Biotech Moves Week ending 02/13/26 $XBI: -2.11% ($122.86) 🔴 $IBB: -1.39% ($172.55) 🔴 Year-to-date $XBI: 0.76% 🟢 $IBB: 2.24% 🟢 See image below. 👇 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune https://t.co/RjwPL6kU1b 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51%"
X Link @BiopharmIQ 2026-02-14T14:08Z 28.9K followers, [----] engagements

"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune Pax for Cancer 📉 $UPB -47% VALIANT Trial Results $MCRB -42% Program and Corporate Updates $CHRS -20% Pricing of Public Offering $1.75/sh $OKYO -19% Pricing of $20M Offering $1.85/sh $RGNX -14% Regulatory Update on RGX-121 BLA See image below. *** AD momentum continues. $NKTR maintenance data + early Ph2a from $EVMN in a"
X Link @BiopharmIQ 2026-02-14T14:02Z 28.9K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing